<DOC>
	<DOCNO>NCT02883790</DOCNO>
	<brief_summary>The aim placebo-controlled randomize study evaluate effect Melatonin 1mg/Zn 30 % VNR/Mg 100 % VNR ( food supplement ) management sleep quality mood alteration cancer patient</brief_summary>
	<brief_title>Effects Somnage® Management Sleep Mood Cancer Patients</brief_title>
	<detailed_description>The main objective study evaluate activity food supplement , make Melatonin , Zinc Magnesium sleep quality cancer patient , compare placebo . Secondary objective evaluate activity Melatonin , Zinc Magnesium quality life , fatigue mood alteration cancer patient . The study also assess safety food supplement investigation . In two small subgroup , voluntary basis , additional assessment do ( arm band , nutritional change diary , DXA one group activity tracker another group )</detailed_description>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1 . Male Females age 18 75 year ( include ) 2 . Pittsburgh Sleep Quality Index ( PSQI ) score ≥ 5 3 . Diagnosed breast , lung colonrectal cancer 4 . Metastatic first chemotherapy line 5 . Planned duration chemotherapy treatment least 63 day 6 . Negative pregnancy test 7 . Patients able swallow 1 . Known hypersensitivity reaction Melatonin , Zinc Magnesium component product 2 . Known current drug alcohol abuse . 3 . Use investigational drug ( ) within 30 day study entry study 4 . Clinically significant finding physical examination presence know clinically significant disease would interfere study evaluation 5 . Patients treated benzodiazepine , hypnotic , anticonvulsant , antipsychotic antidepressant drug two month screen visit 6 . Patients receive plan receive warfarin 7 . Chronic treatment steroid daily dose 10 mg prednisone equivalent product 8 . Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>